Hyperkalemia

An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis

NCT02033317 | PHASE 2 | INTERVENTIONAL

This study assessed the pharmacodynamic effects of patiromer on serum potassium in participants on hemodialysis.

2 Sites

6 Participants

Recruiting

18 Years to 70 Years

If interested, contact clinicaltrials@cslbehring.com for more information

Find closest sites:

SUBMIT

Investigator Site

Orlando,Florida,United States,32809

Investigator Site

Minneapolis,Minnesota,United States,55404

Inclusion Criteria

* Participants on hemodialysis between the ages of 18 and 70 years, with serum potassium levels of at least 5.5 mmol/L
* Adequately dialyzed (Kt/V ≥ 1.2)

Exclusion Criteria

* History of bowel obstruction, swallowing disorders, severe gastrointestinal disorders or major gastrointestinal surgery.
* Severe constipation or irregular bowel habits.
* Unable to consume or tolerate the study-specific diet.

Additional studies can be found at ClinicalTrials.gov